Derjung M Tarn1, Maureen Barrientos2, Angel Y Wang3, Abhijit Ramaprasad3, Margaret C Fang4, Janice B Schwartz2,5. 1. Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California. 2. Division of Geriatrics, University of California, San Francisco, San Francisco, California. 3. University of Chicago, Chicago, Illinois. 4. Division of Hospital Medicine, University of California, San Francisco, San Francisco, California. 5. Division of Clinical Pharmacology, Department of Medicine and Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California.
Abstract
BACKGROUND: Direct-acting oral anticoagulants (DOACs), such as apixaban, are the most commonly prescribed anticoagulants, with advantages in that they do not require routine monitoring. However, less frequent contact with healthcare professionals may contribute to poor patient knowledge about potential interactions between over-the-counter (OTC) products and DOACs. OBJECTIVE: Determine the prevalence of use of OTC products (OTC medications and dietary supplements) with potentially serious apixaban interactions and assess patient knowledge of potential interactions. DESIGN: Cross-sectional survey. SETTING: Academic-affiliated outpatient medical practices in northern and southern California. PARTICIPANTS: A total of 791 English- or Spanish-speaking patients prescribed apixaban. MEASUREMENTS: Use and knowledge of OTC medications and dietary supplements with potentially serious apixaban interactions. RESULTS: Almost all respondents (n = 771; 97.5%) reported OTC product use. Of respondents, 33% (n = 266) took at least one OTC product with potentially serious apixaban interactions daily/most days and 53 (6.7%) took multiple products (mean = 2.6 [SD = 2.6]). Aspirin was taken daily by 116 (14.7%; of which 75 [64.7%] also consumed other potentially interacting OTC products), and some days/as needed by an additional 82 (10.4%). Ibuprofen and naproxen were taken daily/most days by 14 (1.8%) and occasionally by 225 (28.5%). Dietary supplements with potentially serious interactions were taken daily/most days by 160 (20.2%). Approximately 66% of respondents were either uncertain or incorrect about the potential for increased bleeding from combining nonsteroidal anti-inflammatory drugs and apixaban. Less knowledge about OTC products with potentially serious interactions was associated with greater OTC product use (odds ratio = 0.54; 95% confidence interval = 0.35-0.85). CONCLUSION: Significant numbers of patients take OTC products (particularly dietary supplements) with potentially serious interactions with the DOAC apixaban and appear to lack knowledge about potentially harmful interactions. Interventions are needed to educate patients and healthcare providers about potential dangers of taking interacting OTC products in combination with apixaban, and data are needed on outcomes associated with concomitant apixaban-OTC product use. J Am Geriatr Soc 68:155-162, 2019.
BACKGROUND: Direct-acting oral anticoagulants (DOACs), such as apixaban, are the most commonly prescribed anticoagulants, with advantages in that they do not require routine monitoring. However, less frequent contact with healthcare professionals may contribute to poor patient knowledge about potential interactions between over-the-counter (OTC) products and DOACs. OBJECTIVE: Determine the prevalence of use of OTC products (OTC medications and dietary supplements) with potentially serious apixaban interactions and assess patient knowledge of potential interactions. DESIGN: Cross-sectional survey. SETTING: Academic-affiliated outpatient medical practices in northern and southern California. PARTICIPANTS: A total of 791 English- or Spanish-speaking patients prescribed apixaban. MEASUREMENTS: Use and knowledge of OTC medications and dietary supplements with potentially serious apixaban interactions. RESULTS: Almost all respondents (n = 771; 97.5%) reported OTC product use. Of respondents, 33% (n = 266) took at least one OTC product with potentially serious apixaban interactions daily/most days and 53 (6.7%) took multiple products (mean = 2.6 [SD = 2.6]). Aspirin was taken daily by 116 (14.7%; of which 75 [64.7%] also consumed other potentially interacting OTC products), and some days/as needed by an additional 82 (10.4%). Ibuprofen and naproxen were taken daily/most days by 14 (1.8%) and occasionally by 225 (28.5%). Dietary supplements with potentially serious interactions were taken daily/most days by 160 (20.2%). Approximately 66% of respondents were either uncertain or incorrect about the potential for increased bleeding from combining nonsteroidal anti-inflammatory drugs and apixaban. Less knowledge about OTC products with potentially serious interactions was associated with greater OTC product use (odds ratio = 0.54; 95% confidence interval = 0.35-0.85). CONCLUSION: Significant numbers of patients take OTC products (particularly dietary supplements) with potentially serious interactions with the DOAC apixaban and appear to lack knowledge about potentially harmful interactions. Interventions are needed to educate patients and healthcare providers about potential dangers of taking interacting OTC products in combination with apixaban, and data are needed on outcomes associated with concomitant apixaban-OTC product use. J Am Geriatr Soc 68:155-162, 2019.
Authors: Tracey Holsinger; Brenda L Plassman; Karen M Stechuchak; James R Burke; Cynthia J Coffman; John W Williams Journal: J Am Geriatr Soc Date: 2012-05-30 Impact factor: 5.562
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Derjung M Tarn; Arun Karlamangla; Ian D Coulter; Debora A Paterniti; Lyndee Knox; Peter S Khang; Ka-Kit Hui; Neil S Wenger Journal: Patient Educ Couns Date: 2015-03-30
Authors: Martin Wawruch; Magdalena Kuzelova; Tatiana Foltanova; Elena Ondriasova; Jan Luha; Andrej Dukat; Jan Murin; Rashmi Shah Journal: Int J Clin Pharm Date: 2012-10-27
Authors: Derjung M Tarn; Debora A Paterniti; Jeffrey S Good; Ian D Coulter; James M Galliher; Richard L Kravitz; Arun S Karlamangla; Neil S Wenger Journal: Patient Educ Couns Date: 2013-03-07
Authors: Wesley T O'Neal; Pratik B Sandesara; J'Neka S Claxton; Richard F MacLehose; Lin Y Chen; Lindsay G S Bengtson; Alanna M Chamberlain; Faye L Norby; Pamela L Lutsey; Alvaro Alonso Journal: J Am Heart Assoc Date: 2018-03-10 Impact factor: 5.501
Authors: Nikolaos Tsoukalas; Norman Brito-Dellan; Carme Font; Taylor Butler; Cristhiam M Rojas-Hernandez; Thomas Butler; Carmen Escalante Journal: Support Care Cancer Date: 2022-08-06 Impact factor: 3.359
Authors: Hsiang-Wen Lin; Elizabeth H Chang; Yu Ko; Chun-Yu Wang; Yu-Shan Wang; Okti Ratna Mafruhah; Shang-Hua Wu; Yu-Chieh Chen; Yen-Ming Huang Journal: Int J Environ Res Public Health Date: 2020-09-23 Impact factor: 3.390
Authors: Ana Sánchez-Fuentes; José Miguel Rivera-Caravaca; Raquel López-Gálvez; Francisco Marín; Vanessa Roldán Journal: Front Cardiovasc Med Date: 2022-01-17